Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...
Rare Disease Patients Face Barriers in Access and Care
An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.
Independent.ie4d
Around the Districts: Dunlavin, Hollywood and Kiltegan
The 200-page journal includes an article about the massacre on Dunlavin green in 1798, and other articles on Hollywood, ...
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges
PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...
Design Therapeutics: Not A Complete Washout Despite Setback
Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...
Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Pharmabiz15d
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...
Finanznachrichten16d
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion ...
American Association of Individual Investors17d
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Down 59.50%
Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 59.50%, which has investors questioning if this is right time to ...
BioSpace18d
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid ...
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...